In vivo characterization of human myofibrillar myopathy genes in zebrafish  by Bührdel, John B. et al.
lable at ScienceDirect
Biochemical and Biophysical Research Communications 461 (2015) 217e223Contents lists avaiBiochemical and Biophysical Research Communications
journal homepage: www.elsevier .com/locate/ybbrcIn vivo characterization of human myoﬁbrillar myopathy genes in
zebraﬁsh
John B. Bührdel a, Soﬁa Hirth a, Mirjam Keßler a, S€oren Westphal a, Monika Forster a,
Linda Manta a, Gerhard Wiche b, Benedikt Schoser c, Joachim Schessl c, Rolf Schr€oder d,
Christoph S. Clemen e, Ludwig Eichinger e, Dieter O. Fürst f, Peter F.M. van der Ven f,
Wolfgang Rottbauer a, *, Steffen Just a, *
a Department of Internal Medicine II, University of Ulm, 89081 Ulm, Germany
b Department of Biochemistry and Cell Biology, Max F. Perutz Laboratories, University of Vienna, 1030 Vienna, Austria
c Department of Neurology, Friedrich-Baur-Institut, Ludwig-Maximilians-University, Munich, Germany
d Institute of Neuropathology, University Hospital Erlangen, 91054 Erlangen, Germany
e Institute for Biochemistry I, University of Cologne, 50931 K€oln, Germany
f Institute for Cell Biology, University of Bonn, 53121 Bonn, Germanya r t i c l e i n f o
Article history:
Received 3 March 2015
Available online 9 April 2015
Keywords:
Myoﬁbrillar myopathy
Zebraﬁsh
Reverse genetics
Skeletal muscle
Cardiac muscle* Corresponding authors. Department of Internal M
Albert-Einstein-Allee 23, 89081 Ulm, Germany. Fax: þ
E-mail addresses:Wolfgang.Rottbauer@uniklinik-u
Just@uniklinik-ulm.de (S. Just).
http://dx.doi.org/10.1016/j.bbrc.2015.03.149
0006-291X/© 2015 The Authors. Published by Elseviea b s t r a c t
Myoﬁbrillar myopathies (MFM) are progressive diseases of human heart and skeletal muscle with a
severe impact on life quality and expectancy of affected patients. Although recently several disease genes
for myoﬁbrillar myopathies could be identiﬁed, today most genetic causes and particularly the associated
mechanisms and signaling events that lead from the mutation to the disease phenotype are still mostly
unknown. To assess whether the zebraﬁsh is a suitable model system to validate MFM candidate genes
using targeted antisense-mediated knock-down strategies, we here speciﬁcally inactivated known hu-
man MFM disease genes and evaluated the resulting muscular and cardiac phenotypes functionally and
structurally. Consistently, targeted ablation of MFM genes in zebraﬁsh led to compromised skeletal
muscle function mostly due to myoﬁbrillar degeneration as well as severe heart failure. Similar to what
was shown in MFM patients, MFM gene-deﬁcient zebraﬁsh showed pronounced gene-speciﬁc pheno-
typic and structural differences. In summary, our results indicate that the zebraﬁsh is a suitable model to
functionally and structurally evaluate novel MFM disease genes in vivo.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Myoﬁbrillar myopathy (MFM) is a muscular dystrophy deﬁned
by the deposition of myoﬁbrillar proteins into Desmin-positive
protein aggregates and myoﬁbrillar degeneration [1], severely
affecting the quality of life of these patients. Mutations in a variety
of sarcomeric and cytoskeletal proteins resulting in MFM such as
aB-Crystallin, BAG3, Desmin, DNAJB6, FHL1, Filamin C, Myotilin,
Plectin, VCP and ZASP [1,2,3,4,5] have been identiﬁed so far. Most
forms of myoﬁbrillar myopathy are inherited by monogenic point
mutations with a dominant negative effect [3]. Today no causativeedicine II, University of Ulm,
49 731 500 45159.
lm.de (W. Rottbauer), Steffen.
r Inc. This is an open access articleor ameliorating therapy for this signiﬁcant cohort of hereditary
myopathies is available, as the molecular mechanisms that trans-
late the different MFM gene mutations into the pathological fea-
tures observed in MFM patients are not well understood [1,6].
Animal model systems are mostly lacking predominantly due to
their early embryonic lethality [7], but are instrumental to gain
novel insights into the molecular mechanisms that translate from
the mutation to the pathology [6].
Due to their transparency, accessibility for genetic modiﬁcation
and particularly the evolutionary conserved genetic and molecular
mechanisms that control muscle development and function in
zebraﬁsh and mammals, the zebraﬁsh emerged as a vertebrate
model system especially to study human striated muscle diseases
such as cardiomyopathies or muscular dystrophies [8,9,10]. Here
we study the in vivo role of MFM genes by inactivation studies in
zebraﬁsh to analyze MFM gene function on a molecular, cellularunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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modiﬁed antisense oligonucleotide-mediated gene knock-down
has been developed as an elegant and powerful approach to
rapidly evaluate the impact of candidate genes on muscle devel-
opment and function [8,11,12,13]. We demonstrate that targeted
inactivation of MFM genes in zebraﬁsh led to a severe myopathy
accompanied by sarcomeric degeneration, however, without
pathological protein aggregation. We introduce the zebraﬁsh as a
suitablemodel system to dissect the in vivo role of known and novel
MFM-related genes that is crucial to decipher the pathomechan-
isms of MFM and ﬁnally to evaluate therapeutic options for patients
suffering from MFM.
2. Materials and methods
2.1. Zebraﬁsh strains
Care and breeding of zebraﬁsh was carried out essentially as
described [11]. Wild-type ﬁsh of the TE strain were used. The pre-
sent study was performed after appropriate institutional approvals
were secured, which conform to EU Directive 2010/63/EU.
2.2. Morpholino microinjections
Antisense oligonucleotides were directed against the trans-
lational start-sites or splice-sites of the respective genes. Each
Morpholino was then injected in at least four different dosages into
>100 wild-type embryos at the one-cell stage to empirically
determine the optimal Morpholino dosage. The resulting pheno-
types were analyzed at consecutive developmental stages, a stan-
dard control-oligonucleotidewas injected at identical dosages. MO-
BAG3 [14], MO-ZASP [15], MO-cmlc1 [16] and MO-plcg1 [17] were
described before.
2.3. RNA in situ hybridization, immunostaining, immunoblotting
and birefringence analysis
Whole-mount RNA in situ hybridization was carried out as
described [11]. Immunostaining of adult zebraﬁsh cardiomyocytes
was conducted using antibodies against BAG3 (Genetex #102396)
and Desmin (Progen #10570) as described [18]. T12 antibody,
recognizing an epitope of Titin close to the Z-disk, was described
before [19]. Immunoblotting was conducted with antibodies
against Pan-Cadherin (Abcam #ab16505) and Desmin (Sigma
#D8281) [11]. Birefringence analysis were performed and analyzed
as described [13].Table 1
Summary of MFM gene expression data gained by either in situ hybridization or IF-
staining.
Gene name Heart Skeletal muscle
aB-crystallin-a  
aB-crystallin-b  
desmin-a  
desmin-b 
BAG3  
dnajb6-a 
dnajb6-b 
fhl1-a  
fhl1-b  
ﬁlamin C-a 
ﬁlamin C-b 
myotilin  
plectin-a  
plectin-b  
VCP 
ZASP  2.4. Electron microscopy
Zebraﬁsh embryos were ﬁxed (2.5% glutaraldehyde, 1% para-
formaldehyde in 0.1 M phosphate buffer, pH 7.3), post-ﬁxed in 1%
osmium tetroxide, dehydrated and embedded in Epon. Ultrathin
sections (50 nm) were contrasted with uranyl acetate and lead
citrate and examined with a Jeol 1400 or Zeiss EM 10 electron
microscope.
2.5. Functional assessment and statistical analysis
Movement assays at 24 hpf and assessments of cardiac
contractility and heart rate were carried out as described [8,13]. If
not noted otherwise, data are presented as average ± S.D. and
analyzed using Student's t-test, a value of p < 0.05 was accepted as
statistically signiﬁcant.
3. Results
3.1. MFM disease genes are conserved between human and
zebraﬁsh
To investigate whether targeted gene inactivation in zebraﬁsh is
suitable for the functional and structural characterization of MFM
disease genes, we ﬁrst identiﬁed the zebraﬁsh orthologs of the
known human MFM genes. Consistently, the identiﬁed orthologs
showed very high amino acid sequence homology to the human
proteins, in particular within their functional domains. Overall,
sequence identity ranged from 41% to 97% (Suppl. Fig. 1). As an
example, the alignment for human Desmin and zebraﬁsh Desmin-a
shows an amino acid identity of 73% (Suppl. Fig. 2A). BAG3 ho-
mology on protein level between human and zebraﬁsh BAG3 is only
41%, whereas functional domains share 77% sequence identity
(Suppl. Fig. 2B), strongly suggesting the conservation of MFM
protein functions across species. Gene duplication is often observed
in the zebraﬁsh, as a result of a genome duplication during teleost
evolution [20]. Gene duplication was observed for aB-crystallin,
desmin, dnajb6, fhl1, ﬁlamin C and plectin (Suppl. Fig. 1).
3.2. MFM genes are strongly expressed in skeletal and heart muscle
cells in zebraﬁsh
In mammals, MFM genes are predominantly expressed in heart
and skeletal muscle cells [6]. We found for all investigated MFM
orthologs increased expression in zebraﬁsh skeletal- and/or heart
muscle bymRNA and protein expression analysis as summarized in
Table 1. In this context, expression was often pronounced during
early muscle development, as demonstrated for desmin-a and
myotilin (Fig. 1AeF). During development expression of desmin-a
became ﬁrst detectable in the developing somites starting from
16 h post fertilization (hpf) (Fig. 1A), and remained restricted to the
heart and skeletal muscle throughout embryogenesis (Fig. 1B). The
observed temporal and spatial expression pattern resembles the
expression of desmin in mice and humans [21]. In addition to genes
solely expressed in muscle tissue such as desmin-a, we observed
expression of MFM-related genes in multiple other non-muscle
tissues. For instance, we found in 18 hpf embryos myotilin mRNA
ubiquitously expressed (Fig. 1D,E). Additionally, both, desmin-a and
myotilinmRNAs showed strong cardiac expression at 24 and 48 hpf
(Fig. 1C,F).
To further evaluate the subcellular localization of the MFM
proteins in muscle cells, we performed immunoﬂuorescence ana-
lyses in cultured adult zebraﬁsh cardiomyocytes (Fig. 1 GeH). We
found similar to the situation in mice and humans [12], zebraﬁsh
BAG3 protein speciﬁcally localized at sarcomeric Z-disks and the
Fig. 1. MFM disease gene expression analysis and knock-down in zebraﬁsh (AeE) Whole-mount antisense RNA in situ hybridization shows desmin-a and myotilin expression in
skeletal muscle ﬁbers at the 14 somite stage and 24 hpf. (C,F) At 24/48 hpf cardiac expression of desmin a/myotilin was observed (arrows). (G) As revealed by co-stainings with an
antibody against Z-disk Titin (T12) or DAPI, respectively, BAG3 localizes to sarcomeric Z-disks and nuclei of zebraﬁsh cardiomyocytes. (H) Desmin is localized at the sarcomeric Z-
disk, scale bars ¼ 10 mm. (I) Percentage of injected embryos showing a myopathic phenotype. (J) Injection of MO-Plecb blocks the splice donor site of exon 7 of Plectin b, leading to
an abnormally short cDNA fragment due to skipping of exon 7. (K) Western-blot analysis shows the reduction of Desmin after injection of MO-Desma. Pan-Cadherin is used as
loading control.
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subcellular localization of zebraﬁsh Desmin and found that Desmin
was also distributed in a striated pattern and similar to mouse and
human Desmin, localized to the Z-disk region. Additionally, Desmin
was also detected outside the sarcomere, most likely representing
densely packed Desmin networks in the cytoskeleton of the muscle
cell (Fig. 1H). In summary, human and zebraﬁsh MFM gene ortho-
logs not only show very high amino acid identity but also conserved
tissue expression as well as subcellular localization patterns, sug-
gesting conserved biological functions between zebraﬁsh and
humans.
3.3. Loss of MFM gene function leads to myopathy in zebraﬁsh
To investigate the structural and functional role of human MFM
genes in zebraﬁsh muscle in vivo, we next inactivated theTable 2
Monitoring of Morpholino knock-down efﬁcacy.
Gene Morpholino abbreviation Splice assay Western blot
aB-crystallin-a MO-Cryaba 
aB-crystallin-b MO-Cryabb 
desmin-a MO-Desma  
desmin-b MO-Desmb  
BAG3 MO-BAG3 
dnajb6-a MO-DNAJB6a 
dnajb6-b MO-DNAJB6b 
fhl1-a MO-FHL1a  
fhl1-b MO-FHL1b  
ﬁlamin C-a MO-Flnca 
ﬁlamin C-b MO-Flncb 
myotilin MO-Myot 
plectin-a MO-Pleca 
plectin-b MO-Plecb 
VCP MO-VCP  
ZASP MO-ZASPidentiﬁed zebraﬁsh MFM orthologs by injecting Morpholino-
modiﬁed antisense oligonucleotides into one-cell-stage wild-type
embryos. All used Morpholinos were blasted against the zebraﬁsh
genomic sequence (Zv8; www.Ensembl.org) and are predicted to
exhibit no cross-reaction with other expressed zebraﬁsh genes
(Suppl. Fig. 3, Table 2). Between 56% (MO-cryabb, 4 ng/embryo)
and 92% (MO-ZASP, 8 ng/embryo) of injected wild-type embryos
(n > 120) developed a homogenous myopathic phenotype. The
efﬁciency for each individual gene inactivation study is summa-
rized in Fig. 1I. Furthermore, to demonstrate the effectiveness of
the knock-downs, we analyzed pre-mRNA splicing by RT-PCR or
protein levels by Western-Blotting (Table 2). For instance, MO-
Plecb is designed to block splicing at the exon 7eintron 7
boundary. Consistently, we detected alternative splicing resulting
in the skipping of exon 7 (116 bp), a frame shift and premature
termination of protein translation (Fig. 1J). Furthermore, as shown
in Fig. 1K, injection of MO-Desma resulted in severely reduced
Desmin protein levels, whereas normal protein levels were
observed in control embryos.
Next, to evaluate the impact on skeletal muscle structure and
function after knock-down of the MFM orthologs in zebraﬁsh, the
individual morphant phenotypes were evaluated in detail. Inacti-
vation of each MFM gene resulted in reduced motility of the mor-
phants shown by voluntary movement measurements at 24 hpf
(Fig. 2AeC). 73 ± 17% of MO-control injected individuals moved
spontaneously in a 10 s timeframe (Fig. 2A). By contrast, 28 ± 9% of
the Desmin-a and only 1 ± 0.5% of ZASP morphants showed
spontaneous movement at 24 hpf (Fig. 2BeD). Other morphants
such as Plectin-b (63 ± 9%) or aB-crystallin-b (57 ± 13%) deﬁcient
embryos were less affected at early stages of development (Fig. 2D).
To analyze the progression of muscle function in these MFM gene
deﬁcient embryos, we additionally analyzed the “touch escape
response” in the morphants at 48 and 72 hpf. Control individuals
reacted rapidly, bending their whole body resulting in an instant
Fig. 2. Loss of MFM gene function results in a progressive motility deﬁciency (AeC) Spontaneous movement assay with false-colored superimposed overviews of 24 hpf control (A)
and MFM morphants (BeC); Red pictures ¼ 0 s; green pictures ¼ 10 s. (D) Summary of voluntary movement at 24 hpf of MFM morphants. (E) Quantiﬁcation of ﬂight reaction to a
touch stimulus of 72 hpf individuals. Darker gray bars indicate the effect of Morpholinos directed against non-MFM genes as controls. Asterisks indicate signiﬁcance compared to
the MO-control group.
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Supplementary Movie 1). We found that all investigated MFM
morphants displayed severe but variable skeletal muscle dysfunc-
tion and that tactile stimulation often only resulted in an insufﬁ-
cient ﬂight reaction (Fig. 2E; Supplementary Movie 2).
Furthermore, we never observed an improvement of motility dur-
ing embryonic development, but regularly a signiﬁcant deteriora-
tion of skeletal muscle function, suggesting a progression of the
myopathy in MFM gene deﬁcient embryos (Fig. 2DeE). A severe
progression of the myopathy was particularly observed for aB-
crystallin, BAG3, DNAJB6, FHL1, Filamin C and Plectin morphant
embryos (Fig. 2E). For instance, in DNAJB6-a morphants sponta-
neous movement was reduced in only 41 ± 8% of the embryos at 24
hpf (Fig. 2D). By contrast, at 72 hpf, 72 ± 8% of the embryos failed to
ﬂight upon touch stimulation (Fig. 2E). Additionally, Plectin-a and
Plectin-b morphants only exhibited a slight reduction of motility at
24 hpf (MO-Pleca 62 ± 6%; MO-Plecb 63 ± 9%), while at 72 hpfmotility was signiﬁcantly reduced compared to controls (MO-Pleca
34 ± 5%; MO-Plecb 29 ± 11%, p-values < 0.001).
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.bbrc.2015.03.149.
To ﬁnally exclude a systematic inﬂuence ofMorpholino injection
on motility of the zebraﬁsh embryo, we also included different
established Morpholinos that provoke a cardiac phenotype such as
MO-cmlc1 (cardiac myosin light chain-1) [16] or MO-plcg1 (phos-
pholipase C, gamma 1) [17] in addition to the standard control
Morpholino. No signiﬁcant inﬂuence on motility was observed for
cMlc1 or Pclg1 morphants (4 ng/embryo, n > 120, in three inde-
pendent experiments) at 24 and 72 hpf (darker gray bars
Fig. 2DeE), implying that the effect of MFM gene inactivation on
skeletal muscle function is speciﬁc.
In summary, all MFM gene deﬁcient embryos showed signiﬁ-
cantly impaired motility, demonstrating the importance of these
genes for the regular function of the musculature in zebraﬁsh.
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disorganization in vivo
To investigate whether impaired motility of MFM morphants is
caused by structural alterations of the muscle, we ﬁrst analyzed
muscle architecture of MFM gene morphants by birefringence
measurements [10,13]. Highly organized muscle tissue polarizes
light, and disorganization of the muscle tissue can be easily visu-
alized by reduction in birefringence signal. Birefringence signal
intensity from the skeletal muscle was severely reduced in MFM
gene deﬁcient embryos, whereas muscle structure was unaffected
in embryos injected with control Morpholino or cardiac-speciﬁc
Morpholinos (Suppl. Fig. 4B,X,Z). For instance, Desmin-a and
DNAJB6-b morphants displayed a reduced birefringence signal
from the skeletal muscle indicating a loss of organized muscle
tissue in these speciﬁc areas (Fig. 3BeC). The quantiﬁcation of the
birefringence data revealed a signiﬁcant reduction of signal in-
tensity in Desmin-a morphants (MO-Desma: 67 ± 26%, p-
value ¼ 0.002), this is even more pronounced in other MFM gene
deﬁcient embryos as shown for DNAJB6-b (MO-DNAJB6b: 48 ± 15%,
p-value < 0.0001) (Fig. 3D).
To further structurally characterize the myopathic phenotype of
MFM gene deﬁcient embryos, muscle ultrastructure was analyzed
by transmission electron microscopy. Control myocytes were
densely packed with sarcomeres composed of highly organized,
precisely aligned thick and thin myoﬁlaments, ﬂanked by well-
deﬁned Z-disks (Fig. 3E,I). Common ultrastructural traits of all
MFM gene morphants muscle were disorganized sarcomeres andFig. 3. Disturbed myoﬁbrillar structure in MFM gene deﬁcient embryos (AeC) Lateral views o
to reduced birefringence in Desmin-a (B) and DNAJB6-b (C) morphants. (D) Quantiﬁcation
MFM gene deﬁcient and control embryos at 72 hpf. (E) Nuclei (dotted arrows) in the skeletal
injected embryos develop highly ordered myoﬁbrils with ordered sarcomeric units, Z-disks
embryos (asterisk). (G) Autophagic pathology in Dnajb6-a morphants. (F,J,K) Mitochondrial a
ﬁber-like structures in Myotilin morphants (arrows). Scale bars 1 mm.rounded muscle cell nuclei (dotted arrows, Fig. 3F,H) in contrast to
the elongated nuclei in control samples (dotted arrow, Fig. 3E). We
were able to detect gene speciﬁc alterations at the ultrastructural
level, such as vacuolizations in themuscle cells of Desmin-a and aB-
crystallin-a morphants (asterisks, Fig. 3F,H). In addition, Desmin-a
and aB-crystallin-b morphants showed a severe reduction in the
number of cristae in mitochondria (arrowheads Fig. 3F, J), while the
cristae in Plectin-b morphants appeared thicker and more electron
dense compared to controls (Fig. 3K). Furthermore, a severe auto-
phagic pathology was observed in DNAJB6-a deﬁcient embryos
(Fig. 3G), with large vesicles resembling an autophagic rimmed-
vacuolar degenerative pathology [2]. Areas devoid of myoﬁbrils
were observed after targeted inactivation of Myotilin function,
containing only stress ﬁber-like structures or premyoﬁbrils with Z-
bodies (arrows, Fig. 3L).
In summary, targeted inactivation of the known MFM genes
resulted in severe myoﬁbrillar disorganization and degeneration. In
addition we found distinct gene-speciﬁc structural alterations that
resemble pathologies also observed in human MFM patients, sup-
porting the usability of the zebraﬁsh model to investigate the
in vivo role of novel MFM genes.
3.5. MFM gene inactivation leads to heart failure in zebraﬁsh
In addition to myopathies, patients suffering from MFM gene
mutations frequently develop heart muscle diseases [4,5]. Hence, to
assess whether targeted inactivation of MFM gene function also
leads to cardiac dysfunction in zebraﬁsh, we evaluated heartf a control zebraﬁsh (A) at 72 hpf showing bright homogenous birefringence compared
of birefringence in Desmin-a and DNAJB6-b morphants. (EeL) Electron microscopy of
muscle are elongated in controls; (F,H) rounded nuclei in myopathic muscle. (I) Control
, M-Bands and A/I regions. (F,H) Vacuolization in MO-Desma and MO-crayaba injected
lteration in Desmin-a, Plectin-b and aB-crystallin-a morphants (arrowheads). (L) Stress
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developed pericardial edemas within 72 hpf (Fig. 4AeD,
Suppl. Fig. 4). As early as 48 hpf, heart rate (Fig. 4EeF) and fractional
shortening of morphant heart chambers were regularly reduced
(Fig. 4GeH). Exemplarily, heart function of aB-crystallin-a, -b and
Myotilin deﬁcient hearts is shown in Fig. 4. Starting from 48 hpf,
aB-crystallin-a, -b andMyotilin-deﬁcient embryos showed severely
reduced heart rates (Fig. 4E) further declining during development
(Fig. 4F). By 72 hpf, fractional shortening of morphant ventricles
was signiﬁcantly reduced to 12% in aB-crystallin-a, 24% in aB-
crystallin-b and 8% in Myotilin-deﬁcient embryos and decreased
further during embryonic development (Fig. 4GeH), while it was as
high as 47% in MO-control injected embryos. Remarkably, whereas
at 48 hpf atrial fractional shortening in Myotilin morphants was
only slightly reduced (46%), it was already decreased in aB-crys-
tallin-b (35%) and dramatically reduced in aB-crystallin-a-deﬁcient
embryos (9%), demonstrating that although inactivation of the
MFM genes consistently led to heart failure, gene speciﬁc differ-
ences in the manifestation of the pathology could be observed. In
this context, an involvement of the cardiac conduction systemwith
arrhythmias is a characteristic feature of human Desmin-related
MFM (Desminopathy) [5]. Interestingly, 20% of Desmin-a-
deﬁcient embryos at 72 hpf frequently showed signiﬁcant ar-
rhythmias and intermittent sinus exit blocks (Suppl. movie 3).
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.bbrc.2015.03.149.
In summary, independent of the targeted MFM gene, the cor-
responding morphant hearts showed reduced systolic contractile
function and beating frequency.
4. Discussion
Genetic animal models are crucial to characterize the molecular
pathomechanisms of MFM, to evaluate novel candidate genes andFig. 4. Loss of MFM gene function results in a cardiomyopathy in zebraﬁsh (AeD) Phenotype
72 hpf. (E,F) Heart rates of MFMmorphants at 48 (E) and 72 hpf (F) are signiﬁcantly reduced.
and ventricular (H) chambers.to identify and test therapeutic options. To systematically evaluate
whether the zebraﬁsh is a suitable model organism to study human
MFM genes, we inactivated these genes and evaluated the resulting
phenotypes. Inactivation of all investigatedMFM genes consistently
led to pronounced myopathy with severely impaired motility and
myoﬁbrillar degeneration. Furthermore, for the majority of the
morphants, we found next to impaired skeletal muscle function
additional phenotypic characteristics such as diminished cardiac
contractility or arrhythmias, which are also frequently found in
MFM patients carrying mutations in the corresponding genes
[1,4,5]. Importantly, several pathological alterations that were
unique to the respective morphant phenotype were observed. In
this context, it is important to note that ultrastructural analysis of
MFM patient biopsies also revealed disease gene speciﬁc alter-
ations [22]. In DNAJB6 deﬁcient embryos we observed an auto-
phagic pathology that resembles the pathology reported in a
Finnish patient suffering from limb-girdle muscular dystrophy due
to a mutation in the DNAJB6 gene [2]. Likewise, ultrastructural
abnormalities observed in our study are often conﬁrmed by ﬁnd-
ings in other MFM gene knockout animal models. For instance,
vacuolization within skeletal myocytes in aB-crystallin deﬁcient
embryos is also observed in aB-crystallin knockout mice [23].
Furthermore, mitochondrial alterations observed in this study in
distinct morphants such as Desmin and aB-crystallin deﬁcient
embryos, is one of the described pathological features of MFM [24].
Mitochondrial pathology is also reported upon overexpression of
mutant variants of the MFM genes aB-crystallin and Desmin in a
cardiomyopathy mouse model [25]. Loss of ZASP/Cypher results in
a skeletal muscle myopathy and heart failure in zebraﬁsh [15] while
ZASP-deﬁciency in mice causes embryonic lethality most likely due
to the cardiac phenotype [7]. The MFM gene-speciﬁc functional,
structural and ultrastructural alterations observed in the mor-
phants that frequently mimic the situation in distinct MFM patients
and MFM animal models strongly supports the use of the zebraﬁshof MO-control (A), MO-Cryaba (B), MO-Cryabb (C) and MO-Myot (D) zebraﬁsh hearts at
(G,H) Fractional shortening at deﬁned developmental stages (48, 72, 96 hpf) of atrial (G)
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disease genes.
Interestingly, ultrastructural examinations of MFM gene deﬁ-
cient muscle cells in zebraﬁsh did not reveal clear protein aggre-
gation as described for human MFM [1,3,4], suggesting that the
complete loss of MFM genes does not result in protein aggregation
and that instead the presence of mutant MFM proteins might be
responsible for aggregate formation. This ﬁnding is not surprising
since the majority of identiﬁed MFM gene mutations seem not to
result in a complete loss of gene function but rather act in a
dominant-negative manner. A recent elegant study by Ruparelia
and coworkers supports this hypothesis [12]. Here, overexpression
of a MFM-associated BAG3 variant (BAG3-P209L) in the zebraﬁsh
muscle results in pronounced protein aggregation, whereas tar-
geted BAG3 inactivation leads to severe myopathic phenotypes
without protein aggregation [12]. Similarly, human ﬁlaminopathies
due to haploinsufﬁciency cause distal myopathy without patho-
logical protein aggregation, whereas mutations that lead to the
expression of toxic proteins result in aggregation of mutant Filamin
C protein together with many other proteins [26]. The analysis of
these human MFM protein aggregates by laser microdissection-
coupled mass spectrometry, led to the identiﬁcation of known
but also novel proteins that are enriched in the aggregates [27].
Whether these novel aggregate-enriched proteins play a role in the
pathogenesis of MFM is not known. In an analogous manner to
what we have shown in this study, these novel putative MFM genes
can now be evaluated in functional genomic studies in zebraﬁsh.
Very recently, powerful genome editing strategies have emerged.
TALEN and CRISPR/Cas9 technologies have been successfully used
to generate stable knock-out but also knock-in zebraﬁsh lines [28].
Therefore, the zebraﬁsh is not only an excellent model system to
study the in vivo roles of novel putative MFM disease genes by loss-
of-function studies as shown here but might also be suitable to
analyze the MFM pathology and pathomechanisms caused by in-
dividual gene mutations in patients using genetically engineered
zebraﬁsh that speciﬁcally express these genetic variants.
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